Insights & Discussion
The traditional formula Danggui Beimu Kushen Wan (DBKW) contains multi-targeting agents that simultaneously act on more than one pathway in prostate cancer.
The study investigated the mechanisms of Danggui Beimu Kushen Wan (DBKW) in relation to prostate cancer. DBKW compounds were identified from previous reviews, potential targets for prostate cancer were determined from a literature search, approved drugs and the Open Targets database. Targets were chosen based on their relationship with protein-protein interaction network analysis for a total of 26 targets connected to three cancer-related pathways. Molecular docking using PyRx and AutoDock Vina was used to screen a total of 621 compounds against 21 targets for prostate cancer, generating multiple docking results.
The results of the research show that a small number of highly-binding compounds from DBKW could strongly and selectively interact with three identified targets. The top five high-binding-affinity compounds were selected to generate a network. The analysis revealed that compounds from all three herbs within DBKW demonstrated high binding affinity against the 21 targets and may exhibit potential biological activities with these targets, thereby acting upon several pathways of prostate cancer simultaneously.
Discover Related Insights
Bruceolic oil emulsion, when combined with androgen antagonists, shows the greatest efficacy in treating prostate cancer amongst Chinese patent medicines.
2024 Medicine Efficacy and safety of Chinese patent medicine in the adjuvant treatment of prostate cancer: A Bayesian network meta-analysis Wang S, Zhang F, Liu J, Qin P
Network Pharmacology Prostate Cancer
A Network Meta-analysis was conducted to review the safety and effectiveness of different Chinese patent medicines in treating prostate cancer. Various databases were systematically searched for randomized controlled trials of Chinese patent medicines until June 1, 2023. The risk of bias in the included studies was assessed using a tool specifically for randomized controlled trials. Main outcome indicators were how effective the medicine was, its impact on Prostate Specific Antigen, and any adverse reaction. Due to varying treatment durations across the studies, Bayesian mesh meta-regression was implemented to investigate the effects of these different courses on efficacy and safety.
The meta-analysis considered 27 articles involving 1885 patients and nine types of Chinese patent medicine. The findings indicated that certain medicines, namely Bruceolic oil emulsion and Compound Kushen injection, showed significant advantages compared to androgen antagonists regarding efficacy and Prostate Specific Antigen level reduction. However, no significant difference was found among all the Chinese patent medicines in terms of adverse reactions. With these findings, it was deduced that the effectiveness of Chinese patent medicines isn't greatly impacted by the duration of treatment and dosage. Overall, the combination of Bruceolic oil emulsion and androgen antagonist emerged as a promising intervention measure.
Chinese herbal medicines (CHMs) possess multiple advantages, including multiple targets, pathways, and low toxicity, for the treatment of prostate cancer.
2023 Chinese Herbal Medicines Chinese herbal medicines for prostate cancer therapy: From experimental research to clinical practice Kong F, Wang C, Zhang J, Wang X, Sun B, Xiao X, et al.
Review Article Chinese Herbal Medicine Prostate Cancer
The research team undertook an in-depth review of experimental research and clinical practices related to the use of CHMs for prostate cancer treatment, with the data being sourced from PubMed, Embase, and Web of Science. The focus of the review was on recent studies published within the last five years. The research identified five CHM formulas and six single CHM extracts, along with 12 CHM-derived compounds.
The research findings demonstrated that CHMs induced apoptosis, autophagy, and cell cycle arrest in prostate cancer cells, and concurrently suppressed angiogenesis, proliferation, and cell migration. The CHMs also displayed efficacy in overturning drug resistance and in enhancing anti-tumor immunity. The modes of action were identified as the phosphatidylinositol 3-kinase/protein kinase-B/mammalian target of rapamycin, androgen receptor, epidermal growth factor receptor, and Wnt/beta-catenin signaling pathways which are known to play key roles in the development of prostate cancer. Additionally, the researchers discussed the benefits of CHMs in treating hormone-sensitive and castration-resistant prostate cancer.
Cocoa bean husk, a by-product of cocoa processing, exhibits potent antioxidant and anticancer effects on prostate cancer cells due to its high phenolic compound content.
2021 Molecular & Cellular Toxicology Antioxidant and apoptotic activity of cocoa bean husk extract on prostate cancer cells Choi J, Yang C, Lim W, Song G, Choi H
Experimental Study Cocoa Prostate Cancer
The methodology of the study involved fractionating ethanol crude extract of cocoa bean husk (CBH) and comparing the total polyphenol and flavonoid content, as well as radical scavenging activities, of the various fractions. The phenolic compounds present in the ethanol ethyl acetate (EAF) and butanol (BF) fractions were further analysed using High-Performance Liquid Chromatography (HPLC). These fractions were then applied to prostate cancer cell lines PC3 and DU145 to ascertain their impact.
The results indicated that the ethyl acetate fraction exhibited the highest phytochemical content and antioxidant activity, closely followed by the butanol fraction. The presence of abundant phenolic compounds, namely catechin, epicatechin, and procyanidin B, was observed in both fractions. Moreover, both fractions induced apoptosis and DNA fragmentation in the prostate cancer cells in a concentration-dependant manner, demonstrating their potential anticancer effects.
Pomegranate juice and its bioactive components may serve as cost-effective, next-generation non-pharmacologic anticancer therapies, particularly against colorectal and prostate cancer.
2021 Current Drug Delivery Pomegranate, its Components, and Modern Deliverable Formulations as Potential Botanicals in the Prevention and Treatment of Various Cancers Hussein L, Gouda M, Buttar HS
Review Article Anticancer Colorectal Cancer Pomegranate
Methodology: The present review was undertaken to provide current information on the impact of pomegranate juice and its bioactive elements, critically focusing on the effects on the most common six types of cancer. The inherent polyphenolic compounds of pomegranate, such as ellagitannins and punicalagin, are known to have substantial antioxidant capability which has been evaluated through in vitro and in vivo studies. These compounds' ability to avert free radicals and design metal-chelates in biological tissues have offered a useful basis to extrapolate their impact on various types of cancers.
Discussion of Results: The findings indicate that the antioxidant and anti-inflammatory properties of pomegranate possess significant antimutagenic and antiproliferative activities, which proved to be beneficial in modifying gene expression, moderating cellular mechanisms, and limiting the metastasis of cancerous cells. In addition to this, there are reports from a few clinical trials showing the potential of pomegranate ingredients to prevent and treat cancer, notably colorectal and prostate cancer. It’s been noticed that the pomegranate driven therapies may prove to be a cost-effective alternative to costly chemotherapies which often carry drug resistances and severe side effects. Such therapies could offer lesser side effects, making them potential candidates for future non-pharmacologic anticancer treatments.
Jiawei Danggui Beimu Kushen pills were shown to be effective in treating prostate cancer, improving patients' quality of life and potentially regulating serum PSA levels.
2021 Evidence-Based Complementary and Alternative Medicine Clinical Effects of Jiawei Danggui Beimu Kushen Pills in the Treatment of Prostate Cancer and Their Influence on the Expression of Serum Prostate Specific Antigen Zhao H, Ren Z, Wang G
Randomised Controlled Trial Jia Wei Dang Gui Bei Mu Ku Shen Pills Prostate Cancer
In this study, 234 patients suffering from prostate cancer were randomly assigned into two groups: an observation group and a control group, with 117 patients in each. The control group were administered oral bicalutamide tablets, while the observation group received Jiawei Danggui Beimu Kushen pills in addition to the control group's treatment. Numerous factors such as the treatment effectiveness, scores related to symptoms, immune function and quality of life were compared before and after the treatment. The levels of serum PSA and f-PSA in the patients were also monitored and compared at different intervals during the treatment.
After the treatment, the observation group showed a higher effective rate than the control group. The scores related to symptoms were reduced in both groups post treatment, but more so in the observation group. The quality-of-life scores increased in both groups but were particularly higher in the observation group. The levels of serum PSA and f-PSA were noted to decrease as the treatment time increased and were significantly lower in the observation group after 180 days of treatment. The observation group also showed a higher five-year cumulative survival rate. There was no significant difference in the occurrence of dizziness, fatigue, and gastrointestinal reactions; however, rates of dysuria and hematuria were found to be significantly less in the observation group. The pills were effective in reducing IPSS score and TCM syndrome scores, alleviating pain, and enhancing the quality of life.
Sign In
Users not signed in are limited to viewing the 5 most recent items of content.